131 related articles for article (PubMed ID: 25223524)
1. Inter- and intra-individual comparative study of two gadolinium-based agents: A pilot study.
Shin KS; AlObaidy M; Ramalho M; Jeon YH; Burke LM; Altun E; Stallings CG; Semelka RC
Abdom Imaging; 2015 Apr; 40(4):865-74. PubMed ID: 25223524
[TBL] [Abstract][Full Text] [Related]
2. Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study.
Semelka RC; Hernandes Mde A; Stallings CG; Castillo M
Magn Reson Imaging; 2013 Jan; 31(1):96-101. PubMed ID: 22898688
[TBL] [Abstract][Full Text] [Related]
3. Less is better? Intraindividual and interindividual comparison between 0.075 mmol/kg of gadobenate dimeglumine and 0.1 mmol/kg of gadoterate meglumine for cranial MRI.
Khouri Chalouhi K; Papini GDE; Bandirali M; Sconfienza LM; Di Leo G; Sardanelli F
Eur J Radiol; 2014 Jul; 83(7):1245-1249. PubMed ID: 24816087
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of a high relaxivity contrast agent administered at half dose in dynamic susceptibility contrast MRI of brain gliomas.
Crisi G; Filice S; Erb G; Bozzetti F
J Magn Reson Imaging; 2017 Feb; 45(2):500-506. PubMed ID: 27373976
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
[TBL] [Abstract][Full Text] [Related]
6. Contrast-enhanced MRA of the renal and aorto-iliac-femoral arteries: comparison of gadobenate dimeglumine and gadofosveset trisodium.
Iezzi R; Soulez G; Thurnher S; Schneider G; Kirchin MA; Shen N; Pirovano G; Spinazzi A
Eur J Radiol; 2011 Feb; 77(2):358-68. PubMed ID: 19679417
[TBL] [Abstract][Full Text] [Related]
7. [Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)].
Herborn CU; Jäger-Booth I; Lodemann KP; Spinazzi A; Goyen M
Rofo; 2009 Jul; 181(7):652-7. PubMed ID: 19291607
[TBL] [Abstract][Full Text] [Related]
8. Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations.
de Campos RO; Heredia V; Ramalho M; De Toni MS; Lugo-Somolinos A; Fuller ER; Semelka RC
AJR Am J Roentgenol; 2011 Mar; 196(3):545-52. PubMed ID: 21343495
[TBL] [Abstract][Full Text] [Related]
9. Assessment of nonischemic fibrosis in hypertrophic cardiomyopathy: comparison of gadopentetate dimeglumine and gadobenate dimeglumine for enhanced cardiovascular magnetic resonance imaging.
Rudolph A; von Knobelsdorff-Brenkenhoff F; Wassmuth R; Prothmann M; Utz W; Schulz-Menger J
J Magn Reson Imaging; 2014 May; 39(5):1153-60. PubMed ID: 24151119
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, intra-individual comparison of single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine for MR angiography of the peripheral arteries (the Peripheral VALUE Study).
Wang J; Yan F; Liu J; Lu J; Li D; Luan J; Wang X; Li Y; Iezzi R; De Cobelli F
J Magn Reson Imaging; 2013 Oct; 38(4):926-37. PubMed ID: 23371919
[TBL] [Abstract][Full Text] [Related]
11. Acute side effects of three commonly used gadolinium contrast agents in the paediatric population.
Neeley C; Moritz M; Brown JJ; Zhou Y
Br J Radiol; 2016 Jul; 89(1063):20160027. PubMed ID: 27194459
[TBL] [Abstract][Full Text] [Related]
12. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
Bauner KU; Reiser MF; Huber AM
Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
[TBL] [Abstract][Full Text] [Related]
13. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
Knopp MV; Bourne MW; Sardanelli F; Wasser MN; Bonomo L; Boetes C; Müller-Schimpfle M; Hall-Craggs MA; Hamm B; Orlacchio A; Bartolozzi C; Kessler M; Fischer U; Schneider G; Oudkerk M; Teh WL; Gehl HB; Salerio I; Pirovano G; La Noce A; Kirchin MA; Spinazzi A
AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457
[TBL] [Abstract][Full Text] [Related]
14. Three-dimensional multiphase time-resolved low-dose contrast-enhanced magnetic resonance angiography using TWIST on a 32-channel coil at 3 T: a quantitative and qualitative comparison of a conventional gadolinium chelate with a high-relaxivity agent.
Giesel FL; Runge V; Kirchin M; Mehndiratta A; Gerigk L; Corell B; von Gall C; Kauczor HU; Essig M
J Comput Assist Tomogr; 2010; 34(5):678-83. PubMed ID: 20861769
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Low-Dose Higher-Relaxivity and Standard-Dose Lower-Relaxivity Contrast Media for Delayed-Enhancement MRI: A Blinded Randomized Crossover Study.
Cheong BY; Duran C; Preventza OA; Muthupillai R
AJR Am J Roentgenol; 2015 Sep; 205(3):533-9. PubMed ID: 26295638
[TBL] [Abstract][Full Text] [Related]
16. Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting.
Anzalone N; Scarabino T; Venturi C; Cristaudo C; Tartaro A; Scotti G; Zimatore D; Floris R; Carriero A; Longo M; Cirillo M; Cova MA; Gatti S; Voth M; Colosimo C
Eur J Radiol; 2013 Jan; 82(1):139-45. PubMed ID: 21890295
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S
Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
[TBL] [Abstract][Full Text] [Related]
18. A Structured Survey on Adverse Events Occurring Within 24 Hours After Intravenous Exposure to Gadodiamide or Gadoterate Meglumine: A Controlled Prospective Comparison Study.
Parillo M; Sapienza M; Arpaia F; Magnani F; Mallio CA; DʼAlessio P; Quattrocchi CC
Invest Radiol; 2019 Apr; 54(4):191-197. PubMed ID: 30379729
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T.
Attenberger UI; Runge VM; Jackson CB; Baumann S; Birkemeier K; Michaely HJ; Schoenberg SO; Reiser MF; Wintersperger BJ
Invest Radiol; 2009 May; 44(5):251-6. PubMed ID: 19550376
[TBL] [Abstract][Full Text] [Related]
20. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections.
Abujudeh HH; Kosaraju VK; Kaewlai R
AJR Am J Roentgenol; 2010 Feb; 194(2):430-4. PubMed ID: 20093606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
